Jawaid Tabinda, Elbarougy Doaa E, Lavu Sravanthi, Buia Guillaume, Senum Sarah R, Olinger Eric, Yang Hana, McDonnell Shannon K, Bublitz Joshua T, Ma Jun, Audrézet Marie-Pierre, Madsen Charles D, Schauer Rachel S, Baker Tracy A, Gregory Adriana V, Orr Sarah E, Barroso-Gil Miguel, Neatu Ruxandra, Joli Giancarlo, Dahl Neera K, Kline Timothy L, Gillion Valentine, Dahan Karin, Jouret Francois, Perrone Ronald D, Steinman Theodore I, Peters Dorien J M, Gitomer Berenice Y, Watnick Terry J, Coto Eliecer, Chebib Fouad T, Hogan Marie C, Olson Janet E, Larson Nicholas B, Ars Elisabet, Halbritter Jan, Demoulin Nathalie, Torres Vicente E, Sayer John A, Cornec-Le Gall Emilie, Harris Peter C
Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota.
Inserm, UMR 1078, GGB, CHU Brest, University of Brest, Brest, France.
J Am Soc Nephrol. 2025 Jun 1;36(6):1056-1071. doi: 10.1681/ASN.0000000613. Epub 2025 Feb 3.
Loss-of-function and variants were enriched in polycystic kidney/liver groups and International Classification of Diseases–coded cystic individuals in population cohorts. The ALG8 and ALG9 kidney phenotypes were usually mild to moderate, and lower eGFR or kidney failure was rare. pathogenic variants sometimes resulted in severe polycystic liver disease.
Autosomal dominant polycystic kidney disease (ADPKD) is a common, inherited nephropathy often resulting in kidney failure. It is genetically heterogeneous; along with the major genes, and , at least eight others have been suggested. pathogenic variants have been associated with autosomal dominant polycystic liver disease and implicated in ADPKD, while has been suggested as an ADPKD gene, but details of the phenotypes and penetrance are unclear.
We screened >3900 families with cystic kidneys and/or livers using global approaches to detect or pathogenic variants. In addition, population cohorts with sequence data (Genomics England 100K Genomics Project, UK Biobank, and Mayo Clinic Biobank [MCBB]) were screened for / pathogenic variants.
Multicenter screening of individuals with polycystic kidney and/or liver disease identified 51 (1.3%) ALG8 (7 multiplex) and 23 (0.6%) ALG9 (5 multiplex) families—frequencies that were approximately 10× and approximately 24× greater than nonpolycystic kidney disease controls. Analysis of individuals with polycystic kidney disease phenotypes in 100K Genomics Project, UK Biobank, and MCBB identified nine ALG8 (0.39%) and nine ALG9 (0.39%) families, an enriched frequency over controls. Two individuals had and pathogenic changes. Eighty-nine percent of individuals with ALG8 mutations with imaging in the entire MCBB had kidney cysts (50%, >10 cysts), with greater median kidney and liver cyst numbers than controls. For ALG9, 78% had kidney cysts (27%, >10 cysts). Individuals with ALG8 mutations typically had mild cystic kidneys with limited enlargement. Liver cysts were common (71%), with enlarged livers (>2L) found in 11 of 62 patients, although surgical intervention was rare. The ALG9 kidney phenotype was also of mild cystic kidneys, but enlarged livers were rare; for both genes, CKD or kidney failure were rare.
and are defined as cystic kidney/liver genes but with limited penetrance for lower eGFR.
功能丧失和变异在多囊肾/肝组以及人群队列中按国际疾病分类编码的囊性个体中富集。ALG8和ALG9的肾脏表型通常为轻度至中度,低估算肾小球滤过率(eGFR)或肾衰竭很少见。致病性变异有时会导致严重的多囊肝病。
常染色体显性遗传性多囊肾病(ADPKD)是一种常见的遗传性肾病,常导致肾衰竭。其具有遗传异质性;除了主要基因PKD1和PKD2外,至少还有其他八个基因被提出。致病性变异与常染色体显性遗传性多囊肝病相关,并与ADPKD有关,而ALG8已被认为是一个ADPKD基因,但表型和外显率的细节尚不清楚。
我们使用全球方法对超过3900个患有囊性肾脏和/或肝脏的家庭进行筛查,以检测ALG8或ALG9致病性变异。此外,对有序列数据的人群队列(英国基因组学英格兰10万基因组计划、英国生物银行和梅奥诊所生物银行[MCBB])进行ALG8/ALG9致病性变异筛查。
对多囊肾和/或肝病个体进行的多中心筛查发现了51个(1.3%)ALG8(7个家系)和23个(0.6%)ALG9(5个家系)家庭,其频率分别比非多囊肾病对照高约10倍和约24倍。对英国基因组学英格兰10万基因组计划、英国生物银行和MCBB中具有多囊肾病表型的个体进行分析,发现了9个ALG8(0.39%)和9个ALG9(0.39%)家庭,频率高于对照。两名个体有ALG8和ALG9致病性改变。在整个MCBB中,89%有ALG8突变且有影像学检查的个体有肾囊肿(50%,囊肿>10个),其肾囊肿和肝囊肿的中位数数量均多于对照。对于ALG9,78%有肾囊肿(27%,囊肿>10个)。有ALG8突变的个体通常有轻度囊性肾,肿大有限。肝囊肿很常见(71%),62例患者中有11例肝脏肿大(>2L),不过手术干预很少见。ALG9的肾脏表型也是轻度囊性肾,但肝脏肿大很少见;对于这两个基因,慢性肾脏病(CKD)或肾衰竭很少见。
ALG8和ALG9被定义为囊性肾/肝基因,但对低eGFR的外显率有限。